SMAD3 and neoplasm: Given that SMAD3, a major transcription factor in TGF-β pathway, acts as a tumor suppressor and its functional disruption was positively associated with CRC progression and metastasis [33], this fusion might lead to SMAD3 dysfunction, consequently suppressing the function of TGF-β pathway.